Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040822 (tremor)
 18,428 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a double-blind, single-dose trial asthmatic children, ages two to six years, received 25, 50 or 100 ug/kg terbutaline and placebo on four consecutive days. After ingestion of all doses and placebo mean pulmonary index score and mean total respiratory resistance (Rrs), measured by forced oscillation decreased significantly at 0.5, 1, 2, 3 and 4 hours, with maximal decrease at two hours. A dose response was apparent but was significant only between doses of 25 ug/kg and 50 ug/kg at four hours. Adverse effects included elevation of heart rate two hours after the 100 ug/kg dose and tremor. In a subsequent nine-week, single-blind trial clinical wheezing was completely prevented by terbutaline 50 ug/kg tid in five of eight patients and by 75 or 100 ug/kg tid in two patients. Baseline Rrs did not decrease. No adverse ophthalmologic, hematologic or biochemical changes were observed.
 ...
PMID:Terbutaline elixir in preschool children with chronic asthma. 50 80

The therapeutic goal for the treatment of asthma should be to suppress bronchial mucosal inflammation with preventive drugs such as inhaled corticosteroids, and to relieve symptoms of wheezing and breathlessness with bronchodilator drugs. The lower recommended doses of inhaled beta 2-agonists produce rapid effective bronchodilatation without systemic adverse effects; higher doses may produce substantial improvements in airway response which may help patients with more severe airflow obstruction. Higher doses of inhaled beta 2-agonists also cause dose-related systemic adverse beta 2 effects including tremor, tachycardia, hypokalaemia and associated electrocardiographic sequelae. In this respect, although fenoterol appears to cause greater extrapulmonary beta 2-mediated adverse effects at higher doses, there is no evidence to suggest that it is any less beta 2-selective. There is also some evidence to suggest that use of regular inhaled beta 2-agonists may cause increased bronchial hyperreactivity and possibly deterioration in disease control. Patients who require such regular use should therefore be given additional anti-inflammatory therapy with inhaled corticosteroids. The recent availability of novel, longer-acting inhaled beta 2-agonists such as salmeterol and formoterol will also make necessary a careful reappraisal of their long term use in patients with asthma.
 ...
PMID:Risks versus benefits of inhaled beta 2-agonists in the management of asthma. 134 63

2,2'-Isobutylidene-bis(4,6-dimethylphenol), an antioxidant, was given orally to pregnant Wistar rats by stomach intubation at the dose levels of 5, 15 or 45 mg/kg body weight during days 7 to 17 of gestation, and the effects of the compound on dams and fetal developments were examined. In the dams at the two higher dose levels of 15 and 45 mg/kg, toxic signs (tremor, startle reflex, salivation, involuntary urination, wheezing and nostril discharge) were observed. Moreover, at the highest dose level, additional toxic signs (lacrimation and vaginal bleeding), suppression in maternal body weight gain and food consumption were observed. However, there was no evidence of an increase in malformations attributable to the treatment with 2,2'-isobutylidene-bis(4,6-dimethyl-phenol) in any of the treated groups. It was concluded that 2,2'-isobutylidene-bis(4,6-dimethylphenol) has no teratogenic effect in rats, though toxic signs were observed in treated dams of the 15 and 45 mg/kg groups.
 ...
PMID:[Studies on the teratogenic potential of 2,2'-isobutylidene-bis (4,6-dimethylphenol) in rats]. 136 2

Beta 2 agonists are best administered by inhalation since this route provides maximum therapeutic effect with minimum side effects. Plasma levels are lower and muscle cramps, tachycardia and tremor less common. Inhalation may be carried out by use pressurised inhalers (with various modification if necessary), by a Rotahaler with Salbutamol powder, and by nebulisers. All have their uses. Apart from their immediate bronchodilator effect, it is customary to give Beta 2-agonists routinely before inhalation beclomethasone, and there is evidence that regular use of Beta 1-agonists has a useful suppressive effect. In severe chronic asthma high doses may be indicated and be effective where conventional doses have failed. The introduction of reliable sustained-release preparation of theophylline and its derivatives together with plasma assays theophylline levels has enabled therapy to be optimal and side effects to be lessened. The therapeutic range is a plasma concentration of 10-20 mg/l. There are large individual variations in hepatic clearance of theophylline, which may also be influenced by age, liver disease, drugs and viral infections. Theophyllines are less effective as bronchodilators than Beta 2-agonists but in chronic severe asthma have a place for their additive effect. They are used most frequently to suppress nocturnal asthma and early morning wheezing.
 ...
PMID:Bronchodilators: beta 2 agonists versus theophylline. 289 40

This study evaluated the administration of albuterol syrup (0.1 mg/kg/6 hr) or placebo to 2- to 6-year old children whose extrinsic asthma was treated with maintenance theophylline in a prerandomized, double-blind crossover study design. Albuterol/theophylline treatment produced peak expiratory flow rates 2 hours after administration that were significantly higher than in the theophylline/placebo-treated group (119.3 L/min versus 83 L/min) p less than 0.01. The theophylline/placebo-treated group also required higher serum concentrations of theophylline to control wheezing, 10.5 micrograms/ml versus 5.0 micrograms/ml (p less than 0.01). The average symptom scores for the albuterol/theophylline-treated patients (72.5) were less than that of theophylline/placebo-treated group (97.6) p less than 0.02. Side effects such as tremor, irritability, or insomnia occurred in only two of 17 patients. Serial EKG recordings demonstrated no evidence of cardiotoxicity, such as arrhythmias, or indication of myocardial injury. The addition of albuterol to theophylline improved control of severe asthma in children 2 to 6 years of age demonstrated by improvement in pulmonary function, decrease in theophylline dosage requirement, and improvement in symptoms. It was free of any known cardiotoxicity.
 ...
PMID:Albuterol syrup in the treatment of asthma. 389 81

The efficacy of metaproterenol (orciprenaline) and theophylline given orally at currently recommended doses was examined in 34 children with chronic asthma using a randomized double-blind cross-over evaluation of four weeks' duration for each active regimen. No serious adverse effects were seen with either medication, but tremor occurred more frequently with metaproterenol (P less than 0.01). No significant differences were observed in the frequency of nausea, vomiting, headache, or insomnia (P greater than 0.05). Symptoms of wheezing, coughing, exercise intolerance, and interference with sleep were more frequently associated with the oral metaproterenol regimen; completely asymptomatic days occurred 50% more frequently in association with theophylline therapy (P less than 0.01). Mean peak flows, performed twice daily during each of the four-week study periods, were 86 and 92% of predicted for metaproterenol and theophylline, respectively (P less than 0.05). Pulmonary function decreased significantly less with theophylline than with metaproterenol among those who completed six minutes of treadmill exercise during both regimens (P less than 0.05). Corticosteroids, used for acute symptoms that failed to respond to the addition of inhaled metaproterenol, were required in four patients during both regimens, in ten patients only during the metaproterenol regimen, and in one patient only during the theophylline regimen (P less than 0.02). Thus, theophylline therapy was associated with fewer adverse effects, fewer symptoms of asthma, better pulmonary function, better exercise tolerance, and less requirements for corticosteroids than was treatment with metaproterenol.
 ...
PMID:Comparison of orally administered metaproterenol and theophylline in the control of chronic asthma. 704 7

A 57 year old man with essential tremor (ET) presented with a 2 year history of paroxysmal attacks of dyspnoea and wheezing. He had been diagnosed as having bronchial asthma, and propanolol was excluded from his treatment. Flow-volume loops showed abrupt changes in maximum flows, with poor reproducibility. A diagnosis of functional upper airway obstruction was confirmed by fibreoptic bronchoscopy. The importance of establishing the precise diagnosis, in order to provide appropriate treatment, is emphasized.
 ...
PMID:Severe upper airway obstruction in essential tremor presenting as asthma. 792 90

Salbutamol in controlled release tablet form was compared to salbutamol in standard tablet form for the management of patients with bronchial asthma. A total of twenty asthmatic patients enrolled in the study were classified into two groups, ten patients each, for a cross-over study. Group 1 received controlled release tablets for a 2 to 3 week period, and were then shifted to standard tablets for another similar period. Group 2 received standard tablets first and was then shifted to controlled release tablets. Patients were required to record symptom scores during therapy, including sleep disturbance, chest tightness, wheezing, cough, sputum production and inhalational bronchodilator use. Measurements of peak expiratory flow rate (PEFR) were also done, as well as record made of side effects experienced. The result showed that a lower symptom score was found in patients receiving controlled release tablets than in patients receiving standard tablets (p < 0.001 for sleep disturbance, p < 0.005 for sputum formation and p < 0.001 for total score). There was a higher PEFR in patients receiving controlled-release tablets than in patients receiving standard tablets (p < 0.001). Side effects with tremor were observed in 30% of both groups of patients with a slightly higher degree in the patients receiving standard tablets (statistically not significant). In conclusion, salbutamol of controlled release tablet form obtains a better therapeutic response than standard tablets in the management of patients with bronchial asthma.
 ...
PMID:Salbutamol in treatment of bronchial asthma--comparison of controlled release tablet with standard tablet. 798 68

Idiopathic environmental intolerance (IEI), also known as multiple chemical sensitivity, is a clinical description for a cluster of symptoms of unknown etiology that have been attributed by patients to multiple environmental exposures when other medical explanations have been excluded. Because allergy has not been clearly demonstrated and current toxicological paradigms for exposure-symptom relationships do not readily accommodate IEI, psychogenic theories have been the focus of a number of investigations. A significantly higher lifetime prevalence of major depression, mood disorders, anxiety disorders, and somatization disorder has been reported among patients with environmental illness compared with that in controls. Symptoms often include anxiety, lightheadedness, impaired mentation, poor coordination, breathlessness (without wheezing), tremor, and abdominal discomfort. Responses to intravenous sodium lactate challenge or single-breath inhalation of 35% carbon dioxide versus a similar breath inhalation of clean air have shown a greater frequency of panic responses in subjects with IEI than in control subjects, although such responses did not occur in all subjects. Preliminary genetic findings suggest an increased frequency of a common genotype with panic disorder patients. The panic responses in a significant proportion of IEI patients opens a therapeutic window of opportunity. Patients in whom panic responses may at least be a contributing factor to their symptoms might be responsive to intervention with psychotherapy to enable their desensitization or deconditioning of responses to odors and other triggers, and/or may be helped by anxiolytic medications, relaxation training, and counseling for stress management.
 ...
PMID:Responses to panic induction procedures in subjects with multiple chemical sensitivity/idiopathic environmental intolerance: understanding the relationship with panic disorder. 1219 4